Lactate dehydrogenase-to-albumin ratio as a potential prognostic indicator in glucocorticoid-treated severe pneumonia: a multicenter retrospective study with external validation - Takeaways - MDSpire

Lactate dehydrogenase-to-albumin ratio as a potential prognostic indicator in glucocorticoid-treated severe pneumonia: a multicenter retrospective study with external validation

  • By

  • Jiayi Lin

  • Jianyi Chen

  • Zhuolin Liu

  • Qiuhong Wen

  • Zetao Zheng

  • Xueyi Liu

  • Zijian Zhu

  • Danfeng Yang

  • Ziyi Zhou

  • Dakai Xiao

  • Chunli Liu

  • May 13, 2026

  • 0 min

Share

  • 1

    The lactate dehydrogenase-to-albumin ratio (LAR) serves as a potential prognostic marker for mortality in severe pneumonia patients treated with glucocorticoids.

  • 2

    High admission LAR (≥10.48) is associated with over a twofold increase in mortality risk at both 30 days and 90 days.

  • 3

    LAR demonstrated improved predictive discrimination compared to traditional severity scores like PSI and CURB-65.

  • 4

    Patients with high LAR received lower glucocorticoid doses but exhibited more rapid clinical progression, indicating a need for optimized intervention.

  • 5

    The study suggests that LAR is an accessible biochemical marker that can enhance risk stratification in glucocorticoid-treated pneumonia patients.

Original Source(s)

Lactate dehydrogenase-to-albumin ratio as a potential prognostic indicator in glucocorticoid-treated severe pneumonia: a multicenter retrospective study with external validation

  • by Jiayi Lin, Jianyi Chen, Zhuolin Liu, Qiuhong Wen, Zetao Zheng, Xueyi Liu, Zijian Zhu, Danfeng Yang, Ziyi Zhou, Dakai Xiao, Chunli Liu

  • May 13, 2026

Related Content

Short Antibiotics Match Outcomes in Pneumonia

Only about one in ten hospitalized patients qualified for shorter therapy in a large US analysis

Case Report: Multiple organ dysfunction syndrome in a preterm infant secondary to respiratory syncytial virus and bacterial co-infection

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.